Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak ® ) in multiple sclerosis (MS) patients. Methods: Litak ® was offered to MS-patients irrespective of disease course. Litak ® 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, Cesar Álvarez-González, Joela Mathews, Amy MacDougall, Andrea Stennett, Xia Zhou, Ozlem Yildiz, Ashok Adams, Lucia Bianchi, Camilla Blain, Christine Chapman, Karen Chung, Cris S Constantinescu, Catherine Dalton, Rachel A Farrell, Leonora Fisniku, Helen Ford, Bruno Gran, Jeremy Hobart, Zhaleh Khaleeli, Miriam Mattoscio, Sue Pavitt, Owen Pearson, Luca Peruzzotti-Jametti, Antonio Scalfari, Basil Sharrack, Eli Silber, Emma C Tallantyre, Stewart Webb, Benjamin P Turner, Monica Marta, Sharmilee Gnanapavan, Gunnar Juliusson, Gavin Giovannoni, David Baker, Klaus Schmierer
Format: article
Language:EN
Published: SAGE Publishing 2021
Subjects:
Neurology. Diseases of the nervous system
RC346-429
Online Access:https://doaj.org/article/bfd4d711187c4be1bbc0bfb3a0440750
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/bfd4d711187c4be1bbc0bfb3a0440750

Similar Items